Pharma Focus Asia

Novo Nordisk Collaborates with Life Edit Therapeutics

Thursday, May 25, 2023

Novo Nordisk and Life Edit Therapeutics announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets.

Under the agreement, Life Edit will receive an upfront cash payment and is eligible to receive potential development, regulatory, and commercial milestones of 335 million US dollars for each of the first two development programmes under the collaboration and up to 250 million dollars for each of the following five development programmes under the collaboration. 

The collaboration between the two companies allows for development of up to seven programmes. Moreover, this opportunity will co-create novel treatments for multiple genetic diseases based on Life Edit’s gene editing technologies.

Combining Life Edit platform and the ability to make any edit anywhere with Novo Nordisk’s deep disease biology and engineering expertise will bring closer in delivering potentially curative therapies for some of the world’s most challenging genetic diseases.
 

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024